Millennium Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Millennium Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-331,258	Closed	-$35.6M	–	7007
2023 Q1	$35.6M	Buy	331,258 +192,098	+138%	+$22.1M	0.02%	914
2022 Q4	$15.3M	Buy	139,160 +134,994	+3,240%	+$8.75M	0.01%	1689
2022 Q3	$246K	Sell	4,166 -103,576	-96%	-$4.74M	﹤0.01%	5514
2022 Q2	$3.04M	Buy	+107,742	New	+$3.12M	﹤0.01%	3285
2021 Q2	–	Sell	-186,157	Closed	-$3.4M	–	7319
2021 Q1	$3.4M	Buy	+186,157	New	+$3.84M	﹤0.01%	3006

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Millennium Management's RXDX Position: Q2 2023 in Review

Millennium Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 331,258 shares — an estimated $35.6M sold.

Millennium Management first reported a position in RXDX in Q1 2021 and held it in 5 quarters. The position peaked at $35.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Millennium Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 331,258 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $35.6M.
Millennium Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Millennium Management's Prometheus Biosciences, Inc. Common Stock position peaked at $35.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.